Anavex Life Sciences Corp (AVXL)

[TomP1]

Well they kinda say it themselves too...

While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX® as their only Alzheimer’s disease medication. These three key measures comprised a cognitive assessment (ADAS-Cog), a functional assessment (ADCS-ADL) and an assessment of the level of brain atrophy (lateral ventricular volume, LVV, as measured by MRI).

However, this is something Anavex needs to get going too:

Study TRx-237-015, was a randomised double-blind placebo-controlled study in 891 subjects